Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported third-quarter 2019 earnings of $2.79 per share, vs. $2.47 per share expected. Revenues grew 23% to $1.26 billion, vs. $1.24 billion expected. Sales of SOLIRIS (eculizumab) came in at $990.5 million, up 12% year-over-year. Raised FY19 revenue guidance to $4.86 – $4.89 billion vs. prior guidance of $4.75 – … Continue reading Alexion Pharmaceuticals, (ALXN): Q3 2019 Earnings Snapshot